Grand River Aseptic Manufacturing (GRAM) addresses this challenge by providing a flexible, deeply collaborative approach as opposed to short-term campaign planning. By aligning manufacturing capacity with long-term client goals, proactively mitigating facility risks through robust redundancy systems, and streamlining the technology transfer process, GRAM secures operational continuity for its partners.

This strategic focus ensures that client products transition smoothly and maintain consistent performance at commercial volumes.

Nick Bykerk, Chief Financial Officer at GRAM shares insight on the company’s approach to  capacity and expansion, facility design and risk mitigation, reducing bottlenecks for clients as products scale up, and improving yield.

Contract Pharma: How does GRAM approach manufacturing capacity and expansion strategies for clients?

Nick Bykerk: At GRAM, capacity planning begins with the client’s long-term commercialization strategy rather than simply the next campaign. We work closely with clients to understand forecast assumptions, launch timelines, market growth expectations, and inventory strategies so that capacity can be aligned with both current and future demand.

Our approach emphasizes flexibility and scalability. We leverage multiple filling technologies and…